1. Home
  2. PAVM vs GNPX Comparison

PAVM vs GNPX Comparison

Compare PAVM & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PAVmed Inc.

PAVM

PAVmed Inc.

HOLD

Current Price

$10.56

Market Cap

7.1M

Sector

Health Care

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$2.01

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAVM
GNPX
Founded
2014
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
6.4M
IPO Year
2016
2018

Fundamental Metrics

Financial Performance
Metric
PAVM
GNPX
Price
$10.56
$2.01
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$510.00
N/A
AVG Volume (30 Days)
3.0M
907.7K
Earning Date
03-24-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$29,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$450.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.00
$1.71
52 Week High
$28.44
$55.00

Technical Indicators

Market Signals
Indicator
PAVM
GNPX
Relative Strength Index (RSI) 56.23 41.61
Support Level $10.24 $1.99
Resistance Level $11.34 $2.29
Average True Range (ATR) 1.34 0.28
MACD -0.22 -0.04
Stochastic Oscillator 40.36 10.74

Price Performance

Historical Comparison
PAVM
GNPX

About PAVM PAVmed Inc.

PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: